Rev1 Ventures, a Columbus, OH-based venture studio that helps entrepreneurs and corporations accelerate innovation, Nationwide Children’s Hospital, and The Ohio State University, announced the launch of a $30m fund.
Rev1 Catalyst Fund III delivers capital and strategic services for pre-seed, seed stage and early-stage healthcare innovators. Following Rev1 Catalyst Fund II, Rev1 NCH Fund, and Rev1 Catalyst Fund, this fund will remain focused on core research-based themes, including gene and cell therapy, neuroscience, biofilms, ocular health, cardiovascular health, and other therapeutics technologies.
Rev1 Catalyst Fund III will invest in nearly a dozen companies over the next five years, with plans to support follow-on funding for successful predecessor fund portfolio company rounds.
To date, Rev1 Catalyst Fund II has invested more than $10 million since launching in 2019, investing in eight unique companies across 16 financial rounds that have raised over $100 million in co-investment and follow-on investment. Rev1 Catalyst Fund and Rev1 NCH Fund have generated more than $450 million in exits, including the acquisitions of Celenex, Myonexus, and Deep Lens.
Led by Tom Walker, President and CEO, Rev1 Ventures accelerates innovation with connections and capital that help entrepreneurs build high-growth tech companies in software, healthcare, and more. Its venture studio platform serves entrepreneurs at their earliest stages while aligning with corporate and research partners to validate customers, build teams, and access funding.
FinSMEs
22/09/2023